Een onderzoek naar de veiligheid, verdraagbaarheid en werkzaamheid van lokale SM04554-oplossing bij mannelijke proefpersonen met androgenetische alopecia (AGA)
Een multicenter, gerandomiseerd, dubbelblind, voertuiggecontroleerd fase 2-onderzoek naar de veiligheid, verdraagbaarheid en werkzaamheid van 0,15% en 0,25% concentraties van topische SM04554-oplossing bij mannelijke proefpersonen met androgenetische alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
California
-
Encinitas, California, Verenigde Staten, 92024
-
San Diego, California, Verenigde Staten, 92123
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06511
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33143
-
West Palm Beach, Florida, Verenigde Staten, 33401
-
-
Indiana
-
Plainfield, Indiana, Verenigde Staten
-
-
Kansas
-
Wichita, Kansas, Verenigde Staten, 67207
-
-
Michigan
-
Clinton Township, Michigan, Verenigde Staten, 48038
-
Detroit, Michigan, Verenigde Staten, 48202
-
-
Minnesota
-
Fridley, Minnesota, Verenigde Staten, 55432
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87106
-
-
New York
-
New York, New York, Verenigde Staten
-
Stony Brook, New York, Verenigde Staten, 11790
-
-
North Carolina
-
Winston-Salem, North Carolina, Verenigde Staten, 27104
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44195
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97210
-
Portland, Oregon, Verenigde Staten, 97223
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78759
-
College Station, Texas, Verenigde Staten, 77845
-
Dallas, Texas, Verenigde Staten, 75246
-
Houston, Texas, Verenigde Staten
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84117
-
-
Virginia
-
Lynchburg, Virginia, Verenigde Staten, 24501
-
Norfolk, Virginia, Verenigde Staten, 23507
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Clinical diagnosis of AGA
- Willing to inform females, with whom they may interact, that they are using a topical investigational product and direct contact should be avoided as potential harm to a fetus is unknown
- Willing to maintain the same hair style as at study start for the duration of the study
- Willing to not use semi-permanent hair products (e.g., color, texturizers, relaxers) for the duration of the study. Daily styling products will be allowed (e.g., hair gel, mousse, styling spray).
- Willing to use a mild non-medicated shampoo and conditioner for the duration of the study
- Willing to receive a small scalp tattoo
- Able to read and understand English
Exclusion Criteria:
- Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia
- Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
- Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized, that are not using an effective method of birth control and are not willing to use an effective method of birth control during the study treatment period until 90 days post last dose of study medication
- Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), cuts and/or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations
- History of surgical correction of hair loss on the scalp
- Previous exposure to SM04554
- Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 24 weeks prior to study start
- Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 12 weeks prior to study start
- History of hair transplants
- Current use of an occlusive wig, hair extensions, or hair weaves
- Participation in any other investigational drug or medical device trial, which included administration of an investigational study medication or medical device, within 30 days or 5 half-lives of the investigational agent, whichever is longer, prior to study start
- Subjects with a history of clinically significant cardiac arrhythmia as determined by the Investigator
- Subjects with clinically significant findings from medical history, clinical laboratory tests, electrocardiogram (ECG), or vital signs that, in the opinion of the Investigator, could interfere with the objectives of the study or put the subject at risk
- Subjects unwilling to refrain from sperm donation during the study treatment period until 90 days post last dose of study medication
- Subjects with pregnant partners at study start
- Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30 days prior to study start
- Use of medicated shampoo or conditioner within 30 days prior to study start
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Topical SM04554 0.15% solution
Topical SM04554 0.15% solution, applied once a day for 90 days |
Study medication application will be performed by the individual subject at approximately the same time each day. |
|
Experimenteel: Topical SM04554 0.25% solution
Topical SM04554 0.25% solution, applied once a day for 90 days |
Study medication application will be performed by the individual subject at approximately the same time each day. |
|
Placebo-vergelijker: Vehicle
Topical vehicle solution, applied once a day for 90 days |
Vehicle solution application will be performed by the individual subject at approximately the same time each day. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change From Baseline in Non-vellus Hair Count
Tijdsspanne: Day 45, Day 90, and Day 135
|
Change from baseline in non-vellus hair count over time. Non-vellus hair count was determined by macrophotography. Standardized macrophotography color photographs of the treatment area were taken on Visit Day 0 (pre-treatment), as well as on Visit Days 45 and 90, and 135. A circular area of the subject's hair 1.9 cm in diameter was clipped to approximately 1 mm in length prior to performing the macrophotography. On Visit Day 0, a scalp tattoo approximately 1 mm in size and located in the center of the target area of hair was applied to anchor the macrophotography. Photos were uploaded from sites to the vendor where blinded assessment of the macrophotography took place. |
Day 45, Day 90, and Day 135
|
|
Change in Subject Assessment of Hair Growth and Quality
Tijdsspanne: Day 45, Day 90, and Day 135
|
Change in Men's Hair Growth Questionnaire (MHGQ) over time as compared to Baseline. The MHGQ is a subject-completed assessment that asks the subject to evaluate his hair growth and quality since the start of the study. |
Day 45, Day 90, and Day 135
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Hair Growth as Assessed by the Investigator
Tijdsspanne: Day 45, Day 90, and Day 135
|
Change in hair growth over time as compared to Baseline, as assessed by the investigator, using a 7-point scale from -3 (greatly decreased) to +3 (greatly increased). Responses were analyzed using logistic regression modeling improvement vs no change/worsening of hair status at each visit. |
Day 45, Day 90, and Day 135
|
|
Impact of AGA on Quality of Life
Tijdsspanne: Day 45, Day 90, and Day 135
|
Change from baseline in subject responses to the Kingsley Alopecia Profile (KAP) questionnaire over time. The KAP is a validated, patient-reported outcome that quantitatively measure the impact androgenetic alopecia on the subject's quality of life. Each of the 38 KAP 5-category Likert-scaled questions was scored +2 'Strongly Agree' to -2 'Strongly Disagree.' The KAP score was summed across all 38 questions for a score ranging from +76 to -76, with higher scores indicating an increasing negative impact on quality of life. Change from baseline was calculated as visit - baseline such that negative values reflecting improving quality of life. |
Day 45, Day 90, and Day 135
|
|
Change From Baseline in Total Sum of Hair Width
Tijdsspanne: Day 45, Day 90, and Day 135
|
Non-vellus hair width was determined by macrophotography. Standardized macrophotography color photographs of the treatment area were taken on Visit Day 0 (pre-treatment), as well as on Visit Days 45 and 90, and 135. A circular area of the subject's hair 1.9 cm in diameter was clipped to approximately 1 mm in length prior to performing the macrophotography. On Visit Day 0, a scalp tattoo approximately 1 mm in size and located in the center of the target area of hair was applied to anchor the macrophotography. Photos were uploaded from sites to the vendor where blinded assessment of the macrophotography took place. While the protocol and SAP listed this outcome as hair density, the actual outcome analyzed was the total sum of non-vellus hair width in microns within the target area provided by macrophotography. |
Day 45, Day 90, and Day 135
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Yusuf Yazici, M.D., Biosplice Therapeutics, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- SM04554-AGA-02
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .